ISRCTN00721331已完成不适用
Efficacy of add-on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double-blind, placebo-controlled trial with an open-label extension phase
Stanley Medical Research Institute (USA)0 个研究点目标入组 40 人开始时间: 2006年5月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Male or female in- or out-patients will be recruited if:
- •1. They are aged 18-65 years
- •2. Have schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) (APA, 1994); defined schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated) or schizo-affective disorder, depressive type
- •3. Receiving one or more conventional antipsychotics at cumulative daily dose of at least 400 mg chlorpromazine equivalents (e.g. haloperidol 12 mg daily) (see Table of Antipsychotic Equivalents), which has remained unchanged (also in terms of dosage) during at least 6 last weeks prior to screening baseline (8 weeks for depot antipsychotics).
- •Table of antipsychotic equivalents (Basire, 2000) oral mg/day: chlorpromazine 100 mg (= 25-50 mg intramuscular (IM) or 250 mg rectal), fluphenazine 2 mg, levomeptromazine - not known, pericyazine 24 mg, perphenazine 8 mg, prochlorperazine 15 mg, promazine 100 mg, thioridazine 100 mg, trifluoperazine 5 mg, benperidol 2 mg, droperidol 4 mg (Short t1/2) or 3 mg IM/intravenous (IV), haloperidol 3 mg or 1.5 mg IM/IV for doses up to 150 mg/day, trifluoperidol 2 mg, flupentixol 2 mg, zuclopentixol 25 mg up to 150 mg/day, pimozide 2 mg (Long t1/2), remoxiprid 75 mg, amisulpride 100 mg, sulpiride 200 mg, loxapine 10 mg depot (mg/week), fluphenazine 5-10 mg (1-12.5 mg), pipothiazine 10 mg (5-12.5 mg), haloperidol 15 mg (5-12.5 mg), flupentixol 10 mg (8-20 mg), zuclopentixol 100 mg (40-100 mg), fluspirilene 2 mg - not fully established.
- •4. Demonstrating less than optimal clinical outcome i.e. experiencing either positive or negative symptoms (disability due to only general symptoms will be insufficient for inclusion) resulting in the illness of at least moderate severity (i.e. 4, moderately ill, or more on the clinical global impression (CGI), severity item) (Guy, 1970)
- •5. The clinical condition has remained stable during the last 6 weeks prior to the baseline visit
- •6. The patient has a level of understanding that enables reasonable cooperation with the investigator and the ability to fulfil the neurocognitive tests
- •7. The patient has given written informed consent
排除标准
- •1. History of allergy or serious adverse events due to mirtazapine
- •2. Previous lack of response to a trial with mirtazapine in daily doses of 30 mg or more during four or more weeks, added to the patient?s current or earlier conventional antipsychotic medication
- •3. Previous lack of response to another antidepressant with affinity to postsynaptic (5-hydroxytryptamine) 5HT2 receptors (e.g. mianserine, trazodone, or nefazodone) used in adequate doses during four or more weeks
- •4. Current atypical antipsychotic medication (e.g. clozapine, risperidone, olanzapine, sertindole, quetiapine, zotepine, ziprasidone, etc.)
- •5. History of non-response to either clozapine or other atypical antipsychotics
- •6. Medical or neurological condition or drug treatment that might put patients at serious risk or bias the assessment of their clinical or mental status (e.g. serious unstable physical illness, epilepsy, organic brain syndrome etc.)
- •7. History of or current bipolar disorder or schizoaffective disorder, bipolar type (patients with schizoaffective disorder, depressive type can participate in the study)
- •8. Substance addiction or abuse within the last three months prior to screening
- •9. Clearly predictable poor compliance
- •10. For females of child-bearing potential: pregnancy, lactation, or inability or unwillingness to use medically acceptable methods of contraception during the study
- •11. Treatment with any antidepressant, mood stabilizer, regular (i.e. four or more times within 1 week) use of sumatriptan, naratriptan, zolmitriptan, or drugs with similar mechanism of action, or buspiron or drugs with similar mechanism of action - within four weeks (for fluoxetine, six weeks) prior to baseline. Accidental use of the drugs for treatment of migraine listed above is forbidden on the day of clinical assessment before the assessment.
- •12. Treatment with antipsychotics other than those currently in use within six weeks prior to baseline
- •13. Treatment with benzodiazepines as follows:
- •a. Regular use (i.e. four or more times weekly) of any benzodiazepines at any doses during any of the last four weeks prior to baseline, if they have being received for less than two months. However, regular use of benzodiazepines is permitted if they are absolutely necessary and have been received during two or more months prior to baseline in stable daily doses not exceeding 30 mg of diazepam or comparable doses of other benzodiazepines, as determined by the table of equivalents (Bazire, 2000).
- •b. Accidental use (i.e. three or less times weekly) of benzodiazepines in daily doses exceeding 30 mg of diazepam or comparable doses of other benzodiazepines (see table of equivalents) (i.e. accidental use of 30 mg or less of diazepam or comparable doses of other benzodiazepines is not a criterion for exclusion). Use of benzodiazepines on the day of clinical assessment is forbidden before the assessment.
- •14. Electroconvulsive therapy (ECT) within three months prior to baseline
- •15. Any clinically relevant abnormality detected during the physical examination or laboratory screening tests and likely to interfere with the conduct of the study
研究者
相似试验
尚未招募
Unknown
A comparative clinical experiment of mirtazapine and amitriptyline in India on patients with recurring symptoms of an upset stomach that have no obvious causeCTRI/2024/01/061596Indian Council of Medical Research (ICMR)
尚未招募
3 期
Comparison of shivering in drugs of Mirtazapine , Dexamethasone and Tramadol after spinal anaesthesiaCTRI/2023/12/060608SRINIVASAN T
招募中
2 期
Prophylactic effect of mirtazapine for carboplatin-induced nausea and vomitingJPRN-jRCTs041220042Endo Junki51
招募中
1 期
The effectiveness of mirtazapine in reducing dependence and the temptation to consume amphetamine and methamphetamine in patientsIRCT20230606058397N1Ahvaz University of Medical Sciences84
招募中
1 期
Comparison of mirtazapine and citalopram in the treatment of depression in patients with breast cancerMajor Depression, Breast Cancer, Mirtazapine, Citalopram.Malignant neoplasm of breast, major depressionC50 , F32IRCT20220406054440N1Gorgan University of Medical Sciences42